A Global Perspective on Biomarkers in Gastrointestinal Cancer

Please note: You must be registered to attend the 2021 International Gastrointestinal, Liver, & Uro-Oncology Conference to attend this symposium. To Register: http://www.igiluc.com

Join us for this CME-certified symposium presented at IGILUC 2021 featuring expert perspectives on molecular testing, predictive biomarkers, and targeted therapy for patients with GI malignancies. Bring your questions for the live Q&A session with the expert panel faculty at the end of the session.

Agenda

  • Histology-Agnostic Biomarkers in GI Malignancies
  • Biomarker-Driven Treatment of Advanced Colorectal Cancer
  • Biomarker-Driven Treatment of Gastric, Esophageal, Gastroesophageal Junction, Pancreatic, and Biliary Tract Cancers
  • Live Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Faculty
Hesham El Ghazaly, MD

Faculty
David H. Ilson, MD, PhD

Professor of Medicine
Weill Cornell Medical College
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Faculty
Eric Van Cutsem, MD, PhD

Professor of Medicine
University of Leuven
Head, Digestive Oncology Unit
University Hospital Gasthuisberg
Leuven, Belgium

Target Audience
This program is intended for global physicians and other healthcare professionals who treat and manage patients with gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply the available data and expert recommendations to determine which biomarkers should be assessed in your patients with gastrointestinal malignancies
  • Plan therapeutic strategies for patients with gastrointestinal malignancies based on predictive biomarker assessment
  • Evaluate the clinical validity, utility, and differences among single biomarker companion diagnostics and available comprehensive genomic testing platforms using next-generation sequencing
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in gastrointestinal malignancies for patient counsel and potential enrollment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.